Resources

immuno-oncology

Transforming T cell therapy for solid tumors using patient-derived HUB Organoids®

immuno-oncology

Application of HUB Organoids in immuno-oncology drug development

oncology

Tumor organoids

Oncology

Minimizing Oncology Drug Failure Rates Using Organoid Modeling and Multi-omic Data

Dr. Sylvia Boj, Chief Scientific Officer Daniella Patton, Principal Scientific Consultant, Genedata

Oncology

Mini-Organs, Major Breakthroughs: Accelerating Oncology Drug Development

Dr. Sylvia Boj, Chief Scientific Officer

organoid screening

10 years of breakthroughs in Organoid Technology: from adult stem cell discovery to changing patients’ lives

Dr. Robert Vries, CEO

INFECTION DISEASE

Patient-Derived Airway Organoids for Modelling Rhinovirus Infection

inflammatory bowel disease

3D In-Vitro Fibroblast-Patient Derived Organoid Co-Culture: A High-Throughput Platform for Inflammatory Bowel Disease Drug Development

immuno-oncology

Reconstructing tumor microenvironment with patient-derived organoids for derisking Immuno-Oncology therapies

oncology

Patient-derived organoids as a reliable screening platform for assessing ADC efficacy and specificity

oncology

Resistant PDO models: Unraveling drug resistance mechanisms for discovering new drug targets

oncology

Patient-derived organoids: A pre-clinical model to assess infection and killing capacity of viral vectors for cancer therapy

oncology

How we enabled our client to bring an oncology clinical candidate to patients within five years

immuno-oncology

Advancing immunotherapy for solid tumors with patient-derived organoids

immuno-oncology

How we enabled our client to assess efficacy and selectivity of a bispecific antibody using organoid-based co-cultures

oncology

Accelerating oncology drug discovery with HUB Organoids®

Blog

Regulators Embrace Organoids: Inside the FDA’s Shift Away from Animal Model

Last week, the FDA announced a transformative shift in drug development policy that monoclonal antibody (mAb) therapeutics may no longer...

Blog

Ask the Expert: Inside the inFOCUS Assay for IBD Drug Discovery

In this "Ask the Expert" interview, Dr. Javier Frias Aldeguer, Senior Scientist at HUB Organoids shares insights into the inFOCUS...

Blog

The KRAS Conundrum: Challenges and strategies for targeted therapies in cancer

KRAS is a proto-oncogene that is crucial in regulating cell growth and division. Mutations in the KRAS gene are commonly...

toxicology

HUB Organoids in Preclinical Toxicology

inflammatory bowel disease

PDO Monolayer for Inflammatory Bowel Disease (IBD)

immuno-oncology

De-risk your immuno-oncology drug development with HUB Organoids®

oncology

Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response

J Exp Clin Cancer Res | 2024 Feb

oncology

Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer

Cell Rep | April 2023

toxicology

Intestinal organoids as an in vitro platform to characterize disposition, metabolism, and safety profile of small molecules

Eur J Pharm Sci | July 2023

infectious disease

Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma

eLife | July 2021

cystic fibrosis

Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids

J Cyst Fibros | May 2021

inflammatory bowel disease

Organoid-Derived Epithelial Monolayer: A Clinically Relevant In Vitro Model for Intestinal

J Vis Exp | July 2021